Navigation Links
Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
Date:4/24/2009

eVoucherRx lowers patients' financial responsibility for their diabetes therapy, positively influencing compliance and persistency; electronic coupon program works in real time at point of dispensing ACCU-CHEK(R) test strips.

INDIANAPOLIS, April 24 /PRNewswire/ -- Roche announced today the launch of its new eVoucherRx(TM) pilot program in California, designed to make it easier for patients with diabetes to receive their co-pay savings on ACCU-CHEK test strips. The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for ACCU-CHEK(R) test strips will not exceed $25. The program provides a discount of up to $40 per month, potentially lowering a patient's cost of blood glucose monitoring supplies by up to $480 per year.

eVoucherRx is a program that works in real time at the point of dispensing, which means patients do not need to do anything other than go to a participating pharmacy. To find a list of participating pharmacies, patients are encouraged to go online and visit www.accu-chek.com/evoucher.

"Lowering the patient's financial responsibility for diabetes therapy positively influences adherence and persistency in the self-management of their disease, especially during these challenging economic times," said Roche Vice President of Marketing Dan Kane. "eVoucherRx also helps prescribing physicians know that more of their patients will be able to afford their diabetes supplies. Our program that means less cost to our patients, it's seamless and hassle-free and it should lead to better health outcomes."

The eVoucherRx program is administered by RelayHealth for patients with commercial third-party health insurance. The program is not open to patients age 65 or older, cash-paying customers, patients on Medicare, Medicaid or those subsidized by other government-funded plans.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management--from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

    For further information, please contact:
    Julie Vincent
    Public Relations Manager
    ACCU-CHEK(R) Brand
    julie.vincent@roche.com
    317-521-1910


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves New Roche West Nile Virus Blood Screening Test
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
6. MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
7. Nations Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract
8. Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments
9. Roche Extends Tender Offer for Ventana
10. Roche Offers Innovative Website Designed to Empower Cancer Patients
11. Neurochem reports results for third quarter of fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: